Interested in investing in a company that is developing ALS and Alzheimer's treatments?
Alpha Cognition Inc. ( $ACOG.V ACOGF ) is in the clinical stages of developing medicines for the treatment of Alzheimer's Disease, ALS, and other under-served neurodegenerative diseases.
One of the drugs they are developing, Alpha-1062, helps with the cognitive effects for Alzheimer's.
A-1062 is very similar to a drug that was approved in the mid-2000s (developed by J&J) but has serious side-effects that are hard for most to bear.
$ACOG's version of the drugs is optimized to minimize these side effects.
$ACOG is also developing Alpha-602 which is a pro granulin gene therapy drug.
A-602 has been shown to help with a number of ALS disease states and could possibly become a curative option for the disease.
$ACOG has $14.4M from their Canadian IPO to use for the commercialization of their drugs.
$ACOG is currently trading at $1.15 (up 2.7%), MC is $70.7M
More info on $ACOG and their drugs here: https://www.alphacognition.com/